Ozempic vs Saxenda - Who's The biggest loser?

18 snips

Nov 23, 2024

This discussion dives into the origins of GLP-1 drugs, highlighting Liraglutide's role in Saxenda and Victoza. Personal stories emphasize the emotional hurdles of weight loss with Saxenda, revealing common challenges users face. Legal battles surrounding Saxenda unveil significant settlements and health claims, prompting a deeper look into gastrointestinal issues linked to clinical trials. The complexities of medication, including usage, side effects, and financial implications, are explored, showcasing the real-world struggles and victories of weight management.

Ask episode

AI Snips

Chapters

Transcript

Episode notes

ANECDOTE

Laurie's Saxenda Journey

Laurie, a mom of seven, started Saxenda in June 2022 after a hysterectomy led to weight gain and health issues.
She chose Saxenda over Ozempic due to the Ozempic shortage and her doctor's recommendation.

ADVICE

Online Support Groups

Before starting Saxenda, Lorrie joined online support groups but advises caution.
These groups offer valuable support but can also amplify negative experiences and worst-case scenarios.

INSIGHT

Food Noise Reduction

Lorrie's primary effect from the first Saxenda dose wasn't reduced hunger but a quieting of food noise.
By day three, she had more mental space freed from constant thoughts about food.

Get the Snipd Podcast app to discover more snips from this episode

Get the app

This week we look backwards in time in order to move forwards. We check out the first GLP1 drugs and take a longer look at Liraglutide which is a GLP1 found in Victoza (diabetes) and Saxenda (weightloss). We also chat to Lorrie and talk in depth about her journey on Saxenda and why she ended up choosing it over Ozempic.

Lorrie faced many challenges on her journey and I highlight three of the main ones that usually anyone faces when first going on a GLP1 medicine for weight loss. We also take a look at the lawsuits currently underway in the USA over Saxenda and how Novo Nordisk has had to pay out millions of dollars to settle, plus we take a look at the numerous lawsuits claiming gastrointestinal issues and is there any link between them and the clinical trials?

Links to Documents:

European Medicines Agency Report on Liraglutide

Australian Public Assessment Report on Liraglutide

SCALE Liragutide Clinical Study 3.0mg dosage

Korean University Study

Contact

investigatingozempic@gmail.com

Special Note

In this Podcast I am ONLY looking at the WEIGHT LOSS EFFECTS of these GLP1 drugs and am not looking at the Diabetic effects. This podcast should not be construed as giving any type of medical advice. I am not a qualified health care professional.

Legal and Medical Disclaimer:

The Investigating Ozempic podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast or materials linked from this podcast is at the user’s own risk. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they may have and should seek the assistance of their health care professionals for any such conditions.

Every care has been taken to obtain accurate information including reaching out to Novo Nordisk for comment - which so far has remained unanswered. We encourage Novo Nordisk to contact me and correct any discrepancies that have been made accidentally and in good faith by the author. This podcast contains my personal opinion which is solely my own and not intended to be construed in any other manner.

Copyright

All rights reserved by Bernadette Fisers. Material in the podcast and any content therein is subject to copyright under Australian law and through international treaties, and applicable law in other countries.

Unless otherwise indicated, we (and/or our third-party licensors) own the copyright and other intellectual property rights in the recording, text, graphics, information, designs, data and other content in this document.